ArticleJournal of natural medicines2021
Shenyan Kangfu tablet alleviates diabetic kidney disease through attenuating inflammation and modulating the gut microbiota.
Article in Journal of natural medicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Global research landscape and trends of metabolomics in diabetic kidney disease: focus on immunometabolic interactions.Frontiers in clinical diabetes and healthcare · 2026Pooled it
- Clinical efficacy, safety, and cost of nine Chinese patent medicines combined with ACEI/ARB in the treatment of early diabetic kidney disease: A network meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Unveiling the Therapeutic Potential of Suyin Detoxification Prescription in Diabetic Nephropathy: A Comprehensive Study Integrating Clinical Efficacy, Network Pharmacology, and Molecular Mechanisms.Journal of diabetes research · 2025Trial
- Gut microbiota-targeted therapies in pediatric chronic kidney disease: gaps and opportunities.Pediatric nephrology (Berlin, Germany) · 2026Review
- Gut Microbiota Dysbiosis and Metabolite Imbalance Mediate Diabetic Kidney Disease Inflammation: Mechanisms and Intervention Strategies Targeting Gut-Kidney Axis and NF-κB/NLRP3 Pathways.Journal of inflammation research · 2026Review
- Research Progress on Pathogenesis of Diabetic Nephropathy and Intervention with Traditional Chinese Medicine.Journal of multidisciplinary healthcare · 2026Review
- Gut Microbiota and Immunoglobulin A Nephropathy: Exploration of Dietary Intervention and Treatment Strategies.Food science & nutrition · 2025Review
- Gut Microbiota and Their Metabolites: The Hidden Driver of Diabetic Nephropathy? Unveiling Gut Microbe's Role in DN.Journal of diabetes · 2025Review
- Research progress in the treatment of lipid metabolism disorder in patients with diabetic kidney disease by the integrated traditional Chinese and Western medicine.Frontiers in endocrinology · 2025Review
- Traditional Chinese medicine improved diabetic kidney disease through targeting gut microbiota.Pharmaceutical biology · 2024Review
- Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome.PloS one · 2024Article
- Toxicity evaluation of processing Evodiae fructus based on intestinal microbiota.Frontiers in microbiology · 2024Article
- A new perspective on proteinuria and drug therapy for diabetic kidney disease.Frontiers in pharmacology · 2024Review
- The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice.International journal of molecular sciences · 2023Article
- The intellectual base and global trends in inflammation of diabetic kidney disease: a bibliometric analysis.Renal failure · 2023Review
- Role of Gut Microbiota, Immune Imbalance, and Allostatic Load in the Occurrence and Development of Diabetic Kidney Disease.Journal of diabetes research · 2023Review
- Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease.Frontiers in immunology · 2023Review
- Association between salivary microbiota and renal function in renal transplant patients during the perioperative period.Frontiers in microbiology · 2023Article
- The role and mechanism of the gut microbiota in the development and treatment of diabetic kidney disease.Frontiers in physiology · 2023Review
- The roles of gut microbiota and its metabolites in diabetic nephropathy.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Inflammation plays a predominant role in the pathogenesis of diabetic kidney disease (DKD). The Shenyan Kangfu tablet (SYKFT) is a prescription of traditional Chinese medicine for treating chronic kidney disease. However, the concrete mechanism is still unclear. According to previous clinical trial, we explored the effects and potential mechanism on DKD in db/db model supplemented with SYKFT. As a result, SYKFT reduced stimulated blood glucose and HbA1c levels, alleviated renal dysfunction, glomerular and tubular damage, and renal inflammation (TNF-α and IL-1β) in db/db mice. The primary mechanistic study illustrated that SYKFT improved renal injury mainly associated with inhibition of NF-κB in vivo and in vitro. This study further observed that SYKFT increased relative abundance of Firmicutes and decreased Bacteroidetes, showing direct correlation between representative microbiota relative abundance and renal function parameters. SYKFT effectively decreased the relative abundance of Bacteroides, and positive correlation between the relative abundance and protein expression of NF-κB, TNF-α and IL-1β predicted that anti-inflammatory activity of SYKFT was associated with modulating the gut microbiota. Therefore, we first demonstrated SYKFT alleviated DKD through regulating renal inflammatory signaling cascades and intestinal microbiota and also pointed out the role of specific gut microbiota in the development of DKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.